ArticleFrontiers in immunology2025

Tislelizumab plus tyrosine kinase inhibitors with TACE improves survival in unresectable hepatocellular carcinoma with clinical predictors and manageable safety.

Fengliang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.